Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Primary prevention ICD: About one-fifth of the so-called SCD-HeFT population, heart failure patients indicated for a primary prevention implantable defibrillator, do not benefit from ICD therapy because their heart failure is too advanced, according to the results of a study by Wayne C. Levy, M.D., University of Washington, et al. that appears in the Sept. 8 issue of Circulation. The study analyzed data from 2,521 patients in the SCD-HeFT trial, the 2005 study that found that ICD therapy reduces overall mortality by 23% in patients with advanced heart failure and low ventricular ejection fraction. Using the Seattle Heart Failure Model, a prediction model based on routinely collected clinical variables, Levy et al. categorized the patients into five risk quintiles based on their predicted all-cause mortality with standard therapy. The study found that patients in the highest risk quintile had a slightly higher risk of mortality with an ICD than without it
You may also be interested in...
Edwards Looks To Smaller-Diameter Transcatheter Valve In 2010
Edwards Lifesciences hopes to overcome one of its biggest competitive disadvantages in the European transcatheter valve market early next year with the planned launch of a smaller-profile product
FDA, Cardiac Safety Research Consortium To Develop AF Ablation Registry
A consortium of academics, manufacturers and government agencies plans to launch a national atrial fibrillation ablation registry, based on input from a variety of stakeholders at a meeting April 27 and 28 at FDA's White Oak, Md., headquarters
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.